(Q40165143)

18 September 2017

title

AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells (English)

1 reference

18 September 2017

Griessinger E

1

1 reference

18 September 2017

Imbert V

2

1 reference

18 September 2017

Lagadec P

3

1 reference

18 September 2017

Gonthier N

4

1 reference

18 September 2017

Dubreuil P

5

1 reference

18 September 2017

Romanelli A

6

1 reference

18 September 2017

Dreano M

7

1 reference

18 September 2017

Peyron JF

8

1 reference

18 September 2017

language of work or name

1 reference

1 March 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

21

1 reference

18 September 2017

issue

5

1 reference

18 September 2017

page(s)

877-885

1 reference

Nuclear factor-kappaB in cancer development and progression

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Aberrant rel/nfkb genes and activity in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

FLT3: ITDoes matter in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

FLT3 tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Drug therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Calculated resistance in cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

NF-kappaB and IKK as therapeutic targets in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

NF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404614

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404614

1 reference

Dimensions Publication ID

18 September 2017

1008559181

0 references

1 reference